A Deeper Look into Immunotherapies in Stage III and Earlier Non-Small Cell Lung Cancer (NSCLC): Improving Clinical and Economic Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

The Era of Immunotherapy in Earlier Stages of Non-Small Cell Lung Cancer (NSCLC): What Managed Care Needs to Know for Improved Clinical and Economic Outcomes is a 3-part live webinar series
that will provide attendees with the latest information in the management of NSCLC

This is Part 1 of the series focusing on improving clinical and economic outcomes in NSCLC

This activity is an archive from the webinar held February 18, 2020

This activity is valid from April 1, 2020 to April 1, 2022

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
AstraZeneca and Merck & Co.

Lung cancer is the worldwide leading cause of cancer-related mortality. The vast majority of these cases (about 85%) are characterized as non-small cell lung cancer (NSCLC). In recent years, NSCLC has been found to have a multidimensional typology and etiology driven by molecular changes in lung tissue. The knowledge that the molecular structure of tumor cells has been altered has led to the development of novel checkpoint inhibitors (ICI). It was only recently that ICIs have approved for treating patients with stage III disease following concurrent chemoradiation therapy, the aim of which is to prevent disease progression.

Upon completion of this activity, participants will be able to:

  • Identify current unmet clinical needs in the management of early stage NSCLC, including stage III disease, and evidence-based recommendations for the care of patients with these tumors

  • Explore how to harness the immune system in the treatment of cancer, mechanisms of action of the immune checkpoint inhibitors, and rationale for use of immunotherapy in stage III NSCLC as well as other earlier disease stage settings of lung cancer

  • Analyze key clinical data on the efficacy and safety of checkpoint inhibitor-based treatment of patients with stage III, locally advanced, unresectable NSCLC whose cancer has not progressed following chemoradiation therapy

  • Recognize the need for interventions that can delay NSCLC progression, and the rationale for using immune-checkpoint inhibitors for this purpose

  • Discuss the key clinical trials assessing immunotherapies and immune-based combinations in earlier stages of lung cancer, and the available data from such trials

Faculty: Leora Horn, MD, MSc, FRCPC
Associate Professor of Medicine
Clinical Director, Thoracic Oncology Research Program
Assistant Vice Chairman for Faculty Development
Vanderbilt Ingram Cancer Center


Dr. Horn has served on an advisory board for AstraZeneca, EMD Serono, Genentech, Incyte, Merck, Pfizer, and Xcovery. She has served as a consultant for Amgen. She has received grant/research support from Boehringer Ingelheim, Bristol-Myers Squibb, and Xcovery.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
AstraZeneca and Merck & Co.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue